Publications by authors named "Eric Sievers"

Claim this Profile
C
Concomitant Surgical Ablation Using a Novel Bipolar Radiofrequency Clamp: Outcomes from the TRAC-AF Registry.
Christian Shults, Armin Kiankhooy, Shaf B Holden, Hetal D Patel, Frans van Wagenberg, Eric Sievers

J Clin Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
It's time to change how we vaccinate for measles.
Benjamin L Sievers, Eric L Sievers

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage.
Ivan D Hanson, Akash Rusia, Andres Palomo, Adam Tawney, Timothy Pow, Eric Sievers

J Am Heart Assoc· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inundative, Dry-Powder, Inhaled Measles Vaccination to Prevent Deaths of Young Children in War-torn Regions.
Benjamin L Sievers, Robert E Sievers, Eric L Sievers

Open Forum Infect Dis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incentivized self-vaccination for global measles eradication.
Benjamin L Sievers, Robert E Sievers, Eric L Sievers

J Virus Erad· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.
Oleg Kruglov, Lisa D S Johnson, Angela Minic, Kimberly Jordan, Robert A Uger, Eric L Sievers

Cancer Immunol Immunother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M Ansell, Michael B Maris, Alexander M Lesokhin, Robert W Chen, Ian W Flinn, Eric L Sievers

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cause and burn.
David Rose, Eric Sievers, Shaun Nichols

Cognition· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antecedent rationalization: Rationalization prior to action.
Eric Thomas Sievers

Behav Brain Sci· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary meningitis due to successfully treated with ceftriaxone in a healthy adult male.
Trager Hintze, Michelle Steed, Eric Sievers, John T Bagwell, Nicola Selfa

IDCases· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD47 in Sézary syndrome with SIRPαFc.
Lisa D S Johnson, Swati Banerjee, Oleg Kruglov, Natasja Nielsen Viller, Steven M Horwitz, Eric L Sievers

Blood Adv· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of a Large-Scale Gopher Tortoise ( Gopherus polyphemus) Mortality Event on a Public Conservation Land in Florida, USA.
Michelina C Dziadzio, Eric R Sievers, Deborah Burr

J Wildl Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Penka S Petrova, Natasja Nielsen Viller, Mark Wong, Xinli Pang, Gloria H Y Lin, Eric L Sievers

Clin Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.
Ajay K Gopal, Barbara Pro, Joseph M Connors, Anas Younes, Andreas Engert, Eric L Sievers

Clin Trials· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Craig H Moskowitz, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Eric L Sievers

Lancet· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
Ajay K Gopal, Robert Chen, Scott E Smith, Stephen M Ansell, Joseph D Rosenblatt, Eric L Sievers

Blood· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates in cancer therapy.
Eric L Sievers, Peter D Senter

Annu Rev Med· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.
Mikkael A Sekeres, Jeffrey E Lancet, Brent L Wood, Laurie E Grove, Larissa Sandalic, Eric L Sievers

Haematologica· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
Nitya Nathwani, Amrita Y Krishnan, Qin Huang, Young Kim, Chatchada Karanes, Eric Sievers

Leuk Lymphoma· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Peter D Senter, Eric L Sievers

Nat Biotechnol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Anas Younes, Ajay K Gopal, Scott E Smith, Stephen M Ansell, Joseph D Rosenblatt, Eric L Sievers

J Clin Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L Bartlett, Joseph D Rosenblatt, Eric L Sievers

J Clin Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Michelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, Ranjana H Advani, Anna R Franklin, Eric L Sievers

Clin Cancer Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.
Beverly J Lange, Richard K Yang, Jacek Gan, Jaquelyn A Hank, Eric L Sievers

Pediatr Blood Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Anas Younes, Nancy L Bartlett, John P Leonard, Dana A Kennedy, Carmel M Lynch, Eric L Sievers

N Engl J Med· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis